Edison Investment Research - Vitec Group (VTC) QuickView: Streamlined and strengthened

Report

Edison Investment Research

QuickView: Streamlined and strengthened

Following a sequence of disposals over the past four years, Vitec is now
focused on its Broadcast and Photographic divisions where it is investing
heavily in innovative products, notably for independent content providers.
The shares are trading at a discount to peers. We see potential for share
price appreciation as the shares rerate on a likely profit rebound in FY16.

08/09/2015 2 EN

Underlying

Vitec Group

Vitec Group designs, manufactures and distributes products and solutions including camera supports, camera mounted electronic accessories, robotic camera systems, prompters, LED lights, mobile power, monitors and bags. Co. is organized in three divisions: Imaging Solutions, which designs, manufactures and distributes equipment for photographic and video cameras; Production Solutions, which designs, manufactures, distributes and provides products and solutions for broadcasters, film and video production companies; and Creative Solutions, which designs, manufactures and distributes products and solutions for content creators, enterprises, broadcasters, and film and video production companies.

See profile

GB0009296665 London Stock Exchange United Kingdom

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Other Reports on these Companies

TheScreener

VITEC GROUP sees an upgrade to Slightly Positive due to a better fundamental star rating

The general evaluation of VITEC GROUP (GB), a company active in the Recreational Products industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 3 out of 4 possible stars while its market behaviour can be considered as moderately risky. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Slightly Positive. As of the analysis date February 18, 2022, the closing price was GBp 1,310.00 and its potential was estimated at GBp 1,564.52.

Free Trial

February 19, 2022 February 19, 2022 1 EN

Ford Equity Research

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stockâ€™s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the we...

EUR 18.48

December 16, 2016 December 16, 2016 2 EN

Edison Investment Research

QuickView: Streamlined and strengthened

Following a sequence of disposals over the past four years, Vitec is now focused on its Broadcast and Photographic divisions where it is investing heavily in innovative products, notably for independent content providers. The shares are trading at a discount to peers. We see potential for share price appreciation as the shares rerate on a likely profit rebound in FY16.

September 8, 2015 September 8, 2015 2 EN

discoverIE Group - FY24 EPS in line; good margin progress

discoverIE anticipates reporting FY24 underlying EPS in line with board expectations. After a period in mid-FY24 of working down inventory, customers appear to be reverting to normal ordering patterns, with Q424 organic revenue growth of 2% y-o-y and 11% q-o-q and a strong pipeline of design wins at year-end. We have revised our forecasts to reflect lower revenue, partly due to a disposal, but maintain our profit forecasts, which results in operating margin expansion in FY24 and FY25.

1h / 52m 1h / 52m 1 EN

Sean Conroy

Sean Conroy

Ultimovacs - Steadfast commitment to UV1 progression

Despite the recent setback with the INITIUM trial (first-line treatment of patients with unresectable or metastatic malignant melanoma), Ultimovacs has reinstated its commitment to press on with its clinical development of its cancer vaccine, UV1, across other target indications. The principal near-term focus will be on the anticipated results of Phase II FOCUS (head and neck cancer) and DOVACC (ovarian cancer) trials in Q324 and H125, respectively, and will inform its subsequent strategic direction. To remain funded to these milestones, the company has enforced stringent cost control measures...

21h / 55m 21h / 55m 1 EN

Sean Conroy

Sean Conroy

OSE Immunotherapeutics - AbbVie deal clears antitrust hurdle

OSE has announced that its licence agreement with AbbVie has cleared antitrust review and has become effective. As previously noted, this is expected to support OSE’s runway extension into 2026, past key milestones and readouts for in-house assets Tedopi (non-small cell lung cancer, US Phase III trials expected to commence in Q224) and Lusvertikimab (ulcerative colitis, Phase II readouts expected in mid-2024). Following the Federal Communications Commission (FCC) mandatory waiting period, OSE is expected to receive the negotiated US$48m upfront payment from AbbVie imminently, as part of its gl...

22h / 7m 22h / 7m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

QuickView: Streamlined and strengthened

VITEC GROUP sees an upgrade to Slightly Positive due to a better fundamental star rating

Ford Equity International Rating and Forecast Report

QuickView: Streamlined and strengthened

discoverIE Group - FY24 EPS in line; good margin progress

Ultimovacs - Steadfast commitment to UV1 progression

OSE Immunotherapeutics - AbbVie deal clears antitrust hurdle

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe